A decade of SGLT2 inhibitors in cardiovascular science: a bibliometric review

Authors : Ahmet Yılmaz

Pages : 461-468

Doi:10.32322/jhsm.1668518

View : 65 | Download : 52

Publication Date : 2025-05-30

Article Type : Research Paper

Abstract :Aims: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have gained significant attention in cardiovascular science due to their cardioprotective and Reno protective effects beyond glucose control. Over the past decade, research in this field has expanded rapidly. This study aims to conduct a bibliometric analysis of global research trends on SGLT2 inhibitors in cardiovascular diseases from 2014 to 2024, evaluating publication output, citation impact, influential contributors, keyword trends, and international collaboration networks. Methods: A bibliometric analysis was performed using the Web of Science (WoS) Core Collection database, focusing on articles published between January 1, 2014, and December 31, 2024, within the “cardiac cardiovascular system” category. VOSviewer software was utilized to visualize author collaborations, institutional affiliations, keyword co-occurrence, and citation distributions. Results: A total of 1,271 articles were analyzed. Research output has increased significantly, particularly after 2020, aligning with key clinical trials on SGLT2 inhibitors. The most prolific journals included Cardiovascular Diabetology, Journal of the American College of Cardiology, and European Journal of Heart Failure. Leading institutions such as Harvard Medical School, University of Toronto, and University of Groningen were identified as major contributors. Citation analysis highlighted high-impact studies on SGLT2 inhibitors’ cardiovascular and renal benefits. Keyword co-occurrence analysis showed that heart failure, diabetes mellitus, and renal protection were dominant themes. The United States, Germany, and China emerged as major players in global collaborations, shaping the research landscape. Conclusion: The bibliometric findings suggest that research on SGLT2 inhibitors in cardiovascular diseases is rapidly evolving, with increasing global contributions and high-impact publications shaping clinical applications. Future studies should focus on long-term cardiovascular and renal outcomes, mechanistic insights, and comparative effectiveness research to further establish SGLT2 inhibitors’ role in cardiovascular medicine.
Keywords : SGLT2 inhibitörleri, kardiyovasküler hastalıklar, kalp yetmezliği, bibliyometrik analiz, atıf etkisi

ORIGINAL ARTICLE URL